VIRUS INFECTION PANEL **DEMO**

FINAL REPORT

AccessionID:2308080052

Name: VIRUS INFECTION PANEL

DEMO

Date of Birth: 01-01-1111

Gender: Male Age: 01

Height: 76 inches Weight: 205 lbs Fasting: FASTING Telephone: 000-000-0000

Street Address:

Email:

Provider Information

Practice Name: DEMO CLIENT, MD Provider Name: DEMO CLIENT, MD

Phlebotomist: 0

Telephone: 000-000-0000 Address: 3521 Leonard Ct, Santa

Clara, CA 95054

Report Information

Ourrent Result Previous Result

In Control Moderate Risk

Specimen Information

Sample Type	Collection Time	Received Time	Report	Final Report Date
Serum	2023-08-08 09:10 (PDT)	2023-08-09 11:29 (PDT)	Virus Infection Panel - P2	2023-08-18 17:11 (PDT)







Date of Birth: 01-01-1111 Accession ID: 2308080052

Service Date: 2023-08-09 11:29 (PDT)

Virus Infection Panel

INTRODUCTION

Vibrant Wellness is pleased to present to you 'Virus Infections' panel to help you make healthy lifestyle and dietary choice in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being. The Vibrant Virus Infections panel is a test to measure antibody levels to a set of infection antigens. The panel is designed to assess an individual's IgG and IgM antibodies to these antigens in serum/dried blood spot.

Methodology:

The Vibrant Virus Infections test is a semi-quantitative assay that detects IgG and IgM antibodies in human serum/DBS for the infection antigens with multiplexed chemiluminescence immunoassay (CLIA) methodology.

Interpretation of Report:

The Virus Infections summary page provides concise information on the list of antigens with antibody titers that are outside the normal reference range. Reference ranges have been established using 500 healthy individuals. Vibrant utilizes proprietary reporter-based analysis which is designed to assay speci c total IgG (subclasses 1, 2, 3, 4) and total IgM antibodies. Additionally, the previous value (if available) is also indicated to help check for improvements every time the test is ordered.

This is followed by a complete list of all antigens tested including IgG and IgM antibody titers. A classi cation of Green denotes a results that is within the normal reference range, the classi cation of Yellow denotes a result that is moderately elevated titer with respect to the reference range and the classi cation of Red denotes a result that is elevated with respect to the normal reference range.

The Vibrant Wellness platform provides tools for you to track and analyze your general wellness pro le. Testing for Virus Infections panel is performed by Vibrant America, a CLIA certi ed lab CLIA#:05D2078809. Vibrant Wellness provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing, browsing, or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to these terms, you shall not access, browse, or use the report or website. The statements in this report have not been evaluated by the Food and Drug Administration and are only meant to be lifestyle choices for potential risk mitigation. Please consult your physician/dietitian for medication, treatment, or lifestyle management. This product is not intended to diagnose, treat, or cure any disease.

Please note:

It is important that you discuss any modi cations to your diet, exercise, and nutritional supplementation with your physician before making any changes. Pediatric reference ranges have not been established for this test.





Date of Birth: 01-01-1111 Accession ID: 2308080052

Service Date: 2023-08-09 11:29 (PDT)

Virus Infection Panel - Summary

Virus Infection In Control: ≤10 Moderate: 10.1-20 Risk: >20 Reference Range: Current Previous **Epstein Barr Virus IgG IgM** IgG IgM (04-26-2021) (04-26-2021) 29.5 Epstein Barr Virus EBNA1

Central nervous system (CNS) complications of Epstein-Barr virus (EBV) infection occur in up to 18% of patients with infectious mononucleosis and include encephalitis, meningitis, and psychiatric abnormalities.48 Antibodies against the EBV nuclear antigen complex (EBNAc) and EBNA-1 have been correlated with increased risk of multiple sclerosis (MS). The role of EBV in the pathogenesis of multiple sclerosis was attributed to molecular mimicry between EBV and central nervous system (CNS) antigen, myelin basic protein (MBP).

Epstein Barr Virus VCA gp125

24.2

4.4

8.1

2.5

Central nervous system (CNS) complications of Epstein-Barr virus (EBV) infection occur in up to 18% of patients with infectious mononucleosis and include encephalitis, meningitis, and psychiatric abnormalities. 48 Antibodies against the EBV nuclear antigen complex (EBNAc) and EBNA-1 have been correlated with increased risk of multiple sclerosis (MS). The role of EBV in the pathogenesis of multiple sclerosis was attributed to molecular mimicry between EBV and central nervous system (CNS) antigen, myelin basic protein (MBP).





Date of Birth: 01-01-1111 Accession ID: 2308080052

Service Date: 2023-08-09 11:29 (PDT)

Virus Infection Panel

Virus Infection				Reference Range: In Control: ≤10 Moder	ate: 10.1-20 Risk: >2
Cytomegalovirus	lgG	Current	lgM	Previou IgG	lgM
Cytomegalovirus EIA Antigen	6.9		7.9	0.9 (04-26-2021) 0.8	4.5 (04-26-2021) 9.3
Cytomegalovirus GlyB	4.1		1.4	(04-26-2021) 1.2 (04-26-2021)	(04-26-2021) 8.7 (04-26-2021)
Cytomegalovirus p150	1.6		5.8	1.3 (04-26-2021) 1.8	2.8 (04-26-2021) 7.5
Cytomegalovirus p28	2.4		6.1	(04-26-2021) 3.3 (04-26-2021)	(04-26-2021) 1.8 (04-26-2021)
Cytomegalovirus p52	2.3		5.1	2.3 (04-26-2021)	8.6 (04-26-2021)
Cytomegalovirus p65	2.2		1.8		
Cytomegalovirus p38	0.9		4.1		
Epstein Barr Virus	lgG	Current	lgM	IgG Previou	ıs IgM 3.7
Epstein Barr Virus EA Antigen	8.6		3.7	(04-26-2021) 22.7 (04-26-2021)	(04-26-2021) 1.2 (04-26-2021)
Epstein Barr Virus EBNA1	29.5		4.3	8.1 (04-26-2021)	2.5 (04-26-2021)
Epstein Barr Virus VCA gp125	24.2		4.4	2.0 (04-26-2021) 6.5 (04-36-2021)	3.1 (04-26-2021) 3.4 (04-26-2021)
Epstein Barr Virus p18	6.9		1.3	(04-26-2021)	(04-26-2021)
Epstein Barr Virus p23	6.7		4.7		
Herpes simplex virus	1.0	Current	7.4	IgG	IgM
HSV-1	0.8		1.1	8.2 (04-26-2021) 9.0 (04-26-2021)	3.0 (04-26-2021) 6.1 (04-26-2021)
HSV-2	lgG		lgM	(04-26-2021)	(04-26-2021)
Human herpesvirus	1.7	Current	1.0	IgG Previou	IgM
HHV-6	1.4		3.6	4.3 (04-26-2021) 7.0 (04-26-2021)	4.9 (04-26-2021) 6.5 (04-26-2021)
HHV-7	lgG		lgM	(04-26-2021)	(04-26-2021)
Streptococcal A	8.5	Current	2.9	IgG Previou	us IgM
Streptococcal A				1.3 (04-26-2021)	and the same

WHITEHOUSE FAMILY

Date of Birth: 01-01-1111 Accession ID: 2308080052

individual may wish to pursue further testing to verify any results

Service Date: 2023-08-09 11:29 (PDT)

Virus Infection Panel

Risk and Limitations

This test has been developed and its performance characteristics determined by Vibrant America LLC., a CLIA certi ed lab. These assays have not been cleared or approved by the U.S. Food and Drug Administration. Vibrant Wellness provides additional contextual information on these tests and provides the report in a more descriptive fashion.

Clinical history and current symptoms of the individual must be considered by the healthcare provider prior to any interventions. Test results should be used as one component of a physician's clinical assessment.

Vibrant Virus Infections panel testing is performed at Vibrant America, a CLIA certi ed laboratory utilizing ISO-13485 developed technology. Vibrant America has effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a speci c test due to circumstances beyond Vibrant's control. Vibrant may re-test a sample to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested

The information in this report is intended for educational purposes only. While every attempt has been made to provide current and accurate information, neither the author nor the publisher can be held accountable for any errors or omissions. Tested individuals may not their experience is not consistent with Vibrant's selected peer reviewed scientic research indings of relative improvement for study groups. The science in this area is still developing and many personal health factors affect diet and health. Since subjects in the scientic studies referenced in this report may have had personal health and other factors different from those of tested individuals, results from these studies may not be representative of the results experienced by tested individuals. Further, some recommendations may or may not be attainable, depending on the tested individual's physical ability or other personal health factors. A limitation of this testing is that many of these scientic studies may have been performed in selected populations only. The interpretations and recommendations are done in the context of these studies, but the results may or may not be relevant to tested individuals of different or mixed ethnicities.

Vibrant Wellness makes no claims as to the diagnostic or therapeutic use of its tests or other informational materials. Vibrant Wellness reports and other information do not constitute medical advice and are not a substitute for professional medical advice. Please consult your healthcare practitioner for questions regarding test results, or before beginning any course of medication, supplementation, or dietary changes



